Published on : May 17, 2016
ALBANY, New York, May 17, 2016: A new research report on the global atrial fibrillation market has been recently added to the vast repository of ResearchMoz.us. The market study, titled “Atrial Fibrillation-Market Insights & Drugs Sales Forecast (AF)-2020,” provides a comprehensive and unbiased analysis of this market based on its historical performance, present status, and its future prospects.
The research report presents an assessment of the driving forces and challenges, highlighting the major trends that are influencing the worldwide atrial fibrillation market. It also offers an evaluation of the performance of the drugs used for the treatment of atrial fibrillation, namely Xarelto, Pradaxa, Eliquis, and Savaysa in this market over the period from 2011 to 2020, taking the key trends and prospects of these drug segments in consideration.
Atrial fibrillation is the most common type of arrhythmia. It causes an irregular and fast heart beat in human beings. Over the past decade, the number of cases related to atrial fibrillation has increased significantly across the world. The increasing incidence of strokes, atrial fibrillation owing to blood clots, and brain damage, propelled by the rising geriatric population, are the key driving forces that have boosted this market in the recent times.
Click here to get more info with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=714516
According to the research report, the global market for atrial fibrillation stood at US$7.2 bn in 2015. Analysts expect this market to reach an estimated value of US$12.5 bn by the end of 2020.
The research report has studied the worldwide market for atrial fibrillation on two fronts: Type of treatment available for atrial fibrillation and the regional spread of this market. Pharmacological drugs and non-pharmacological procedures are the two main types of treatment available for atrial fibrillation in the global arena.
The pharmacological drugs segment leads the overall market with a majority share. Anti-coagulant drugs and anti-arrhythmic drugs are the major pharmacological drugs used for the treatment of atrial fibrillation. The low cost of these drugs is fuelling their demand significantly. In addition to this, the increasing usage of anticoagulants as an add-on treatment to non-pharmacological procedures is likely to drive their demand in the near future, propelling this market during the forecast period, notes the market study.
Based on the geographical distribution of the atrial fibrillation market, the research report identifies the 7 major markets, namely the U.S., Japan, the U.K., France, Italy, Germany, and Spain as the key regional markets for atrial fibrillation.
Boston Scientific Corp., St. Jude Medical Inc., Ncontact Inc., Biotroik Se & Co. Kg, Medtronic Inc., Carima Inc., Cardiofocus Inc., Biosense Webster Inc., and Atricure Inc. are the leading players operating in the global atrial fibrillation market, states the research report.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on email@example.com